HTBX - Heat Biologics, Inc.
| Previous Close | 1.11 |
| Open | 1.11 |
| Bid | 1.05 x 200 |
| Ask | 1.13 x 1000 |
| Day's Range | 1.09 - 1.15 |
| 52 Week Range | 1.09 - 8.30 |
| Volume | 152,066 |
| Avg. Volume | 438,908 |
| Market Cap | 6.287M |
| Beta | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.08 |
| Earnings Date | May 9, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.25 |
- American City Business Journals•yesterday
Heat Bio looks to milestones, $15.5M from offering
Durham’s Heat Biologics (Nasdaq: HTBX) is eyeing a number of important milestones this year and looking to bank about $15.5 million in an offering of common stock and warrants.
- ACCESSWIRE•7 days ago
Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110
- Plans Interim Lung Cancer Phase 2 Readout in Q4 2018 and Final Readout in Q2 2019 - Expects to File IND and Enroll First Patient in ComPACT Trial in Q4 2018 - Anticipates Receipt of $6.9 Million in CPRIT ...
- Simply Wall St.•14 days ago
Who Are Heat Biologics Inc’s (NASDAQ:HTBX) Major Shareholders?
In this analysis, my focus will be on developing a perspective on Heat Biologics Inc’s (NASDAQ:HTBX) latest ownership structure, a less discussed, but important factor. Ownership structure has been foundRead More...
- ACCESSWIRE•last month
Heat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation Platform
100% of non-muscle invasive bladder cancer patients who generated an immune response to low dose HS-410 and also received standard of care BCG remain disease-free after 2 years DURHAM, NC / ACCESSWIRE ...
- American City Business Journals•last month
On heels of adopting 'poison pill', Heat Bio recruits new scientific expertise
On the heels of disclosing last week that the company had adopted a stockholder rights plan – otherwise known as a "poison pill" for protection against hostile takeovers – Durham’s Heat Biologics and its subsidiary Pelican Therapeutics have recruited some new scientific expertise.
- ACCESSWIRE•last month
Heat Biologics and Its Pelican Therapeutics Subsidiary Appoint Anthony Tolcher, M.D., FRCPC, FACP to their Scientific Advisory Boards
DURHAM, NC / ACCESSWIRE / March 19, 2018 / Heat Biologics, Inc. (''Heat'') (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, along ...
- ACCESSWIRE•last month
Heat Biologics to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
DURHAM, NC / ACCESSWIRE / March 14, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, ...
- ACCESSWIRE•last month
Heat Biologics to Present at the BIO-Europe Spring Conference, March 12-14, 2018, in Amsterdam
DURHAM, NC / ACCESSWIRE / March 13, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, ...
- ACCESSWIRE•last month
Heat Biologics Adopts Stockholder Rights Plan
DURHAM, NC / ACCESSWIRE / March 12, 2018 / Heat Biologics, Inc. ("Heat" or the "Company") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's ...
- Simply Wall St.•2 months ago
Has Heat Biologics Inc (NASDAQ:HTBX) Improved Earnings Growth In Recent Times?
For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...
- ACCESSWIRE•2 months ago
Heat Biologics Reports Fiscal Year 2017 Financial Results
DURHAM, NC / ACCESSWIRE / March 2, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, ...
- ACCESSWIRE•2 months ago
Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
- Tumor Shrinkage and Disease Control Demonstrated in a Majority of Evaluable Patients - HS-110 + Nivolumab Combination Showed Durable Responses in Difficult-to-treat Low TIL Patients and Low PD-L1 Patients, ...
- ACCESSWIRE•2 months ago
UPDATE: Heat Biologics to Host Analyst and Investor Event February 28, 2018, to Present Results from its Phase 2 Lung Cancer Study
Event to Be Webcast Live DURHAM, NC / ACCESSWIRE / February 26, 2018 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
- ACCESSWIRE•2 months ago
Heat Biologics Receives Recommendation from Independent Data Monitoring Committee to Continue Enrollment of Phase 2 Clinical Trial for HS-110 and Nivolumab for Treatment of Non-small Cell Lung Cancer
DURHAM, NC / ACCESSWIRE / February 20, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
- ACCESSWIRE•2 months ago
Heat Biologics Announces Poster Presentation of Interim Phase 2 Lung Cancer Clinical Data for HS-110 and Nivolumab at the 2018 Keystone Symposia Conference XI: Immunological Memory: Innate, Adaptive and Beyond
DURHAM, NC / ACCESSWIRE / February 14, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
- ACCESSWIRE•2 months ago
Heat Biologics CEO, Jeff Wolf, to Present at the Upcoming BIO CEO & Investor Conference in New York
DURHAM, NC / ACCESSWIRE / February 7, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
- ACCESSWIRE•3 months ago
Today’s Research Reports on Trending Tickers: Heat Biologics and ImmunoGen
NEW YORK, NY / ACCESSWIRE / February 1, 2018 / U.S. markets rallied late Wednesday to close in the green, with the Dow Jones and S&P 500 posting their best monthly gain since March 2016. The Dow Jones ...
- ACCESSWIRE•3 months ago
Heat Biologics to Host Analyst and Investor Event February 28, 2018 to Present Results from its Phase 2 Lung Cancer Study
Event will Highlight Clinical Data on First 35 Patients Dosed with HS-110 Plus Checkpoint Inhibitor Nivolumab (Opdivo®) DURHAM, NC / ACCESSWIRE / January 30, 2018 / Heat Biologics, Inc. (NASDAQ: HTBX), ...
- American City Business Journals•3 months ago
Heat latest Triangle biopharma to execute reverse stock split
On the heels of Argos Therapeutics (ARGS) executing a one-for-twenty reverse stock split , another Durham-based biopharmaceutical company Heat Biologics (HTBX) has undertaken a one-for-ten reverse stock split of its own. Last year, Heat outlined a new strategy moving forward, focused on combination therapies for the treatment of cancer .
- Simply Wall St.•4 months ago
Should You Be Concerned About Heat Biologics Inc’s (NASDAQ:HTBX) Investors?
In this article, I will take a quick look at Heat Biologics Inc’s (NASDAQ:HTBX) recent ownership structure – an unconventional investing subject, but an important one. Ownership structure of aRead More...
- ACCESSWIRE•5 months ago
Heat Biologics Receives FDA Guidance at Type C Meeting for HS-110 Clinical Trial in the Treatment of Non-small Cell Lung Cancer
DURHAM, NC / ACCESSWIRE / December 7, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against ...
- Simply Wall St.•5 months ago
Want To Invest In Heat Biologics Inc (HTBX)? Here’s How It Performed Lately
For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...
Capital Cube•5 months agoHeat Biologics, Inc. :HTBX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
Categories: Yahoo FinanceGet free summary analysis Heat Biologics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Heat Biologics, Inc. – Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Newlink Genetics Corporation, Cascadian Therapeutics Inc., Celldex Therapeutics, Inc., Onconova Therapeutics Inc. and Xencor, Inc. ... Read more (Read more...)
